Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Daniel Quirk_2023
VIEWPOINTS

Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu

Shots: Daniel started the discussion by speaking about the epidemiology of plaque and briefed about SOTYKTU approved for the treatment of moderate-to-severe Plaque Psoriasis He also elaborated on the results from the P-III registrational studies POETYK PSO-1 and POETYK PSO-2 The interview also talks about how BMS is advancing its product portfolio to deliver innovative…
April 17, 2023

Read more

Exclusive_Anne Arnold_2023
EXCLUSIVE

Anne Arnold, Senior Director, Education & Training at Smile Train Shares Insights on New VR Platform for Pediatric Surgery

Shots:  Anne started by talking about the launch of the first-ever cleft surgery virtual reality platform in collaboration with Biodigital, which simulates surgery on cleft lip and palate, a birth condition  Anne explained how the VSS VR Extension technology enables surgeons worldwide to collaborate in virtual operating rooms, ensuring safer surgery and better outcomes for…
April 11, 2023

Read more

VIEWPOINTS_Martin Mackay_2023
VIEWPOINTS

Martin Mackay, CEO of Rallybio, Shares his Thoughts on the Appointment of Jonathan I. Lieber as Chief Financial Officer

Shots: Martin shared his views on the appointment of Jonathan I. Lieber as the CFO of Rallybio. Martin spoke about Jonathan's educational background and experience while talking to PharmaShots' team He also talked about how Jonathan I. Lieber’s expertise in finance, capital raising, long-range strategic planning, operations, and investor relations can contribute to the long-term…
April 10, 2023

Read more

VIEWPOINTS_Jennifer Davidson1_2023
VIEWPOINTS

Jennifer Davidson, VP, Medical Affairs, Immunology at the Janssen Pharmaceutical Shares Insights from QUASAR Induction Study-I Evaluating Tremfya

Shots: Jennifer talked about the results from QUASAR Induction Study-I evaluating Tremfya in adults with moderately to severely active ulcerative colitis presented at the 2022 American College of Gastroenterology Annual Meeting He also gave an overview of Trefmya focusing on major advances. He also spoke about the epidemiology and etiology of Ulcerative Colitis The interview…
April 6, 2023

Read more

VIEWPOINTS_Scott Stout_2023
VIEWPOINTS

Scott Stout, CEO of MedVector his Views on the Misunderstood FDA’s Guidance on DCTs at 2023 J.P. Morgan Healthcare Conferences

Shots:  Scott gave a brief about the MedVector and shared his personal experience from his treatment of arthritis by participating in the clinical trial  He also elaborated on how MedVector clarified the misunderstanding on FDA’s guidance on DCTs by the clinical research industry at the 41st Annual J.P. Morgan Health Care Conference 2023  The interview…
March 30, 2023

Read more

VIEWPOINTS_Craig Thompson_2023
VIEWPOINTS

Craig Thompson, CEO of Cerevance Shares Insights from the Preclinical Data Presented at the Society for Neuroscience (SFN) 2022

Shots:   Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease  He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…
March 20, 2023

Read more

VIEWPOINTS_Andrea Mugan1_2023
VIEWPOINTS

Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights from the Launch of Digital Patient Support Resource for Ovarian Cancer Patients

Shots:  Andrea talked about the launch of a digital patient support resource by the Ovarian Cancer Commitment (OCC) in co-development with AstraZeneca and other organizations for ovarian cancer patients  She also highlighted how this important resource, named Olivia supports in navigating ovarian cancer diagnosis. This tool is an interactive tool that allows users to access…
March 16, 2023

Read more

VIEWPOINTS_Nirja Patel_2023
VIEWPOINTS

Nirja Patel, Senior International Product Manager at Roche Shares her Views on the US FDA Approval of the PATHWAY anti-HER2 Test

Shots:  Nirja gave the details of the PATHWAY anti-HER2 (4B5) to identify metastatic breast cancer patients with low HER2 expression through its scoring algorithm that helps pathologists to identify “low expressors” of HER2  She told PharmaShots about how this test is able to identify patients who may benefit from Enhertu as a treatment option. She…
March 7, 2023

Read more

Load more